Clinical Trial Update: Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating safety and immunogenicity of three lots of Novartis Meningococcal C Conjugate Vaccine in healthy toddlers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• Novartis Meningococcal C Conjugate Vaccine (Meningococcal C conjugate vaccine)

Snippet

Sponsor: Novartis | Conditions: Meningococcal Disease, Meningococcal Meningitis | Phase 2 | Status: COMPLETED | Results posted: 2014-03-26